Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
– ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol – ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK, July 26, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),…
Comments Off on Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial